Novo Nordisk says CagriSema beat Lilly's tirzepatide on weight loss in REIMAGINE 5 trial

Novo Nordisk says its CagriSema combination delivered superior weight loss versus Eli Lilly's tirzepatide in the REIMAGINE 5 trial. At the 1.0 mg dose of each component, patients lost 12.4% of body weight at week 60 versus 9.1% on tirzepatide.

Detected & updated continuously · Source: Nebula